373P The role of concomitant RAS and BRAF mutations in influencing clinical outcome during BRAF-targeted treatment for metastatic colorectal cancer. - Pretta, A.; Ziranu, P.; Spanu, D.; Lai, E.; Dettori, M.; Manai, C.; Balconi, F.; Intini, R.; S. Murgia; Leone, A.G.; Pozzari, M.; Rasola, C.; et al. (Annals of Oncology, 2022)